Kezar Life Sciences (NASDAQ:KZR) Earns Neutral Rating from HC Wainwright

Kezar Life Sciences (NASDAQ:KZR)‘s stock had its “neutral” rating reissued by research analysts at HC Wainwright in a research report issued on Monday,Benzinga reports.

Several other analysts also recently commented on KZR. William Blair reiterated a “market perform” rating on shares of Kezar Life Sciences in a report on Wednesday, November 13th. Wells Fargo & Company decreased their price objective on shares of Kezar Life Sciences from $20.00 to $11.00 and set an “equal weight” rating for the company in a research note on Thursday, November 14th.

Kezar Life Sciences Price Performance

KZR stock opened at $7.47 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.65 and a current ratio of 7.65. The business has a 50-day simple moving average of $7.55 and a two-hundred day simple moving average of $6.78. The company has a market capitalization of $54.53 million, a P/E ratio of -0.57 and a beta of 0.22. Kezar Life Sciences has a 52-week low of $5.20 and a 52-week high of $11.35.

Kezar Life Sciences (NASDAQ:KZR) last announced its earnings results on Tuesday, November 12th. The company reported ($2.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.03) by $0.25. Research analysts expect that Kezar Life Sciences will post -6.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Kezar Life Sciences

Large investors have recently made changes to their positions in the business. Mackenzie Financial Corp purchased a new position in shares of Kezar Life Sciences in the 2nd quarter worth about $35,000. XTX Topco Ltd boosted its stake in Kezar Life Sciences by 256.1% in the third quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock valued at $40,000 after acquiring an additional 37,504 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Kezar Life Sciences during the 2nd quarter valued at approximately $63,000. Geode Capital Management LLC increased its stake in shares of Kezar Life Sciences by 15.0% during the 3rd quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock worth $485,000 after purchasing an additional 81,678 shares during the last quarter. Finally, Acuitas Investments LLC raised its holdings in shares of Kezar Life Sciences by 42.8% in the 2nd quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock worth $592,000 after purchasing an additional 295,956 shares during the period. 67.90% of the stock is owned by hedge funds and other institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.